Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice
- Conditions
- Parkinson's Disease
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1814
- Registration Number
- NCT01061567
- Locations
- 🇪🇪
Boehringer Ingelheim Investigational Site 115, Järvamaa, Estonia
🇦🇹Boehringer Ingelheim Investigational Site 2, Bad Radkersburg, Austria
🇦🇹Boehringer Ingelheim Investigational Site 19, Graz, Austria
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1452
- Registration Number
- NCT01050062
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 234, Akashi, Japan
🇯🇵Boehringer Ingelheim Investigational Site 237, Amagasaki, Japan
🇯🇵Boehringer Ingelheim Investigational Site 141, Chigasaki, Japan
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 157
- Registration Number
- NCT01040793
- Locations
- 🇧🇪
1222.38.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇦🇹1222.38.4381 Boehringer Ingelheim Investigational Site, Leoben, Austria
🇧🇪1222.38.32004 Boehringer Ingelheim Investigational Site, Brussel, Belgium
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo (for olodaterol BI1744)Drug: Olodaterol (BI1744) LowDrug: Olodaterol (BI1744) HighDrug: Tiotropium 18 mcgDrug: Placebo (for Tiotropium)
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 108
- Registration Number
- NCT01040689
- Locations
- 🇧🇪
1222.39.32003 Boehringer Ingelheim Investigational Site, Genk, Belgium
🇩🇰1222.39.45002 Boehringer Ingelheim Investigational Site, Odense C, Denmark
🇩🇰1222.39.45001 Boehringer Ingelheim Investigational Site, Hvidovre, Denmark
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 122
- Registration Number
- NCT01040728
- Locations
- 🇳🇴
1222.40.47002 Boehringer Ingelheim Investigational Site, Drammen, Norway
🇳🇱1222.40.31002 Boehringer Ingelheim Investigational Site, Eindhoven, Netherlands
🇳🇱1222.40.31003 Boehringer Ingelheim Investigational Site, Breda, Netherlands
Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 233
- Registration Number
- NCT01040403
- Locations
- 🇩🇪
1237.18.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇨🇦1237.18.02003 Boehringer Ingelheim Investigational Site, Point Claire, Quebec, Canada
🇸🇪1237.18.46003 Boehringer Ingelheim Investigational Site, Boden, Sweden
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 151
- Registration Number
- NCT01040130
- Locations
- 🇦🇺
1222.37.6171 Boehringer Ingelheim Investigational Site, Daw Park, South Australia, Australia
🇦🇹1222.37.4371 Boehringer Ingelheim Investigational Site, Gänserndorf, Austria
🇦🇺1222.37.6172 Boehringer Ingelheim Investigational Site, Melbourne, Victoria, Australia
Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01036763
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 173, Heilbronn, Germany
🇩🇪Boehringer Ingelheim Investigational Site 133, Germering, Germany
🇩🇪Boehringer Ingelheim Investigational Site 161, Hamburg, Germany
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 99
- Registration Number
- NCT01024920
- Locations
- 🇵🇱
Onco.Cent. - Instit. of Maria Sklodowskiej-Curie, Warszawa, Poland
🇭🇺University of Pecs Medical School, Dept. of Oncotherapy, Pecs, Hungary
🇵🇱Ziemia Lubelska Oncological Center, Lublin, Lublin, Poland
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
- Conditions
- Neoplasms
- Interventions
- Drug: BI 6727, IV infusion
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT01023958
- Locations
- 🇺🇸
1230.2.5 Boehringer Ingelheim Investigational Site, Beverly Hills, California, United States
🇺🇸1230.2.17 Boehringer Ingelheim Investigational Site, Joliet, Illinois, United States
🇺🇸1230.2.24 Boehringer Ingelheim Investigational Site, Metairie, Louisiana, United States